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Abstract
Epigenetic regulation of gene expression is well known mechanism that regulates cellular senescence of cancer cells. Here
we show that inhibition of DNA methyltransferases (DNMTs) with 5-azacytidine (5-AzaC) or with specific small interfering
RNA (siRNA) against DNMT1 and 3b induced the cellular senescence of human umbilical cord blood-derived multipotent
stem cells (hUCB-MSCs) and increased p16
INK4A and p21
CIP1/WAF1 expression. DNMT inhibition changed histone marks into
the active forms and decreased the methylation of CpG islands in the p16
INK4A and p21
CIP1/WAF1 promoter regions.
Enrichment of EZH2, the key factor that methylates histone H3 lysine 9 and 27 residues, was decreased on the p16
INK4A and
p21
CIP1/WAF1 promoter regions. We found that DNMT inhibition decreased expression levels of Polycomb-group (PcG)
proteins and increased expression of microRNAs (miRNAs), which target PcG proteins. Decreased CpG island methylation
and increased levels of active histone marks at genomic regions encoding miRNAs were observed after 5-AzaC treatment.
Taken together, DNMTs have a critical role in regulating the cellular senescence of hUCB-MSCs through controlling not only
the DNA methylation status but also active/inactive histone marks at genomic regions of PcG-targeting miRNAs and
p16
INK4A and p21
CIP1/WAF1 promoter regions.
Citation: So A-Y, Jung J-W, Lee S, Kim H-S, Kang K-S (2011) DNA Methyltransferase Controls Stem Cell Aging by Regulating BMI1 and EZH2 through
MicroRNAs. PLoS ONE 6(5): e19503. doi:10.1371/journal.pone.0019503
Editor: Brian P. Chadwick, Florida State University, United States of America
Received January 31, 2011; Accepted March 30, 2011; Published May 10, 2011
Copyright:  2011 So et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Research Foundation of Korea (NRF) (MEST,2010-0020265). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kangpub@snu.ac.kr
. These authors contributed equally to this work.
Introduction
Cellular senescence is a significant mechanism for the
maintenance of stem cell self-renewal and multipotency [1,2].
Epigenetic regulatory mechanisms, such as acetylation and
methylation of core histones, DNA methylation and microRNAs
(miRNAs), have been reported to play pivotal roles in regulating
cellular senescence [3]. We have previously shown that the
inhibition of histone deacetylases (HDACs) induces cellular
senescence of human multipotent stem cells (MSCs) by controlling
the balance in the expression levels of polycomb group (PcG) and
jumonji domain containing 3 (JMJD3) proteins [4].
DNA methyltransferase (DNMT) is an enzyme that catalyzes
the transfer of a methyl group to DNA. DNA methylation is one of
the regulatory mechanisms of gene expression by which
transcriptional activity of DNA decreases and DNA stability
increases. DNMT has multiple isoforms, including DNMT1,
DNMT3A and DNMT3B, which have different roles. DNMT1
maintains methylation of DNA, while DNMT3A and DNMT3B
make de novo DNA methylation. It is well known that DNMT over-
expression induces aberrant hypermethylation, which contributes
to silencing tumor suppressor genes in various cancer cells
[5,6,7,8,9]. The promoter region of p16
INK4A, a cyclin dependent
kinase (CDK) inhibitor, is hypermethylated as a result of over-
expression of DNMTs in many cancer cell lines [8,10,11]. The
expression of p21
CIP1/WAF1, another CDK inhibitor, is also
regulated by DNA methylation [12]. Given that CDK inhibitors,
p16
INK4A and p21
CIP1/WAF1 are known key players in cellular
senescence in vitro[13,14], it was assumed that DNMTs might be
involved in cellular senescence of stem cells; however, direct
evidence whether DNMT involves in the regulation of stem cell
aging has not been reported yet. Epigenetic regulatory machin-
eries, such as DNA methylation, histone acetylation, deacetylation
and histone methylation, are associated with and regulated by
each other [15]. Although the primary role of DNMTs is to
methylate DNA, DNMTs are also reported to modulate patterns
of histone acetylation and methylation. Treatment with 5-
azacytidine (5-AzaC), an inhibitor of DNMT analogous to
cytidine, not only inhibits DNMT activity but also affects histone
modification patterns, suggesting that DNMT may modulate core
histone via both direct and indirect mechanisms [16]. PcG
proteins are key factors that translate DNA methylation patterns
into histone modifications. PcGs are comprised of two main PcG
complexes, polycomb repressive complex (PRC) 1 and 2. PRC2
group proteins are involved in the initiation of gene silencing,
whereas PRC1 stabilizes and maintains gene repression. It was
reported that SUZ12, a PRC2 protein, recognizes and binds to
methylated CpG in the genome. Binding of SUZ12 onto
methylated CpG initiates recruitment of EZH2, another PRC2
protein possessing histone methyltransferase activity, to the site of
DNA methlyation and induces methylation of histone H3 at the
lysine 27 residue. BMI-1, a PRC1 protein, is recruited to the
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addition, Jin et al. showed that DNMT3B plays an important role
in controlling histone modification patterns by regulating PRC1
function [18]. Hernandez-Munoz I et al. confirmed that DNMT1
is necessary for proper assembly of the PRC body [19]. In
contrast, histone modification patterns and other patterns of
epigenetic modifiers influence the propensity of genes to become
hypermethylated in cancer [18].
MiRNAs are non-coding RNAs and are smaller than 22
nucleotides. MiRNAs are epigenetic regulators of gene expression
that degrade or inhibit translation of target mRNAs. In many
studies, miRNAs have been reported to target oncogenes, tumor
suppressors in cancer and differentiation markers, which should be
silenced to keep stem cells from differentiating and instead self-
renew [20,21,22,23,24,25,26]. MiRNAs can also regulate other
epigenetic regulators such as DNMT, HDAC, high-mobility group
AT-hook 2 (HMGA2) and PcG [27,28,29,30,31,32,33]. Although
many studies have focused on the target of specific miRNAs,
considering the importance of the biological roles of miRNAs, the
intermediary mechanisms of miRNAs among the epigenetic
regulatory factors should be explored. The possibility of epigenetic
repression, mediated by DNA methylation and histone modifica-
tion of tumor suppressor miRNAs in human cancer cells, has been
reported [34]. Recently, there have been several reports of the
epigenetic control of miRNA clusters [31,35,36]. Briefly, genomic
DNA regions that encode tumor suppressor miRNAs are
inactivated by aberrant hypermethylation in human breast cancer
cell lines. After treatment with 5-aza-29-deoxycytidine (5-Aza-dC),
demethylation of the mir-9-1 genome and increases in mir-9-1
expression were observed [35]. In our previous study, we showed
that inhibition of HDACs up-regulated miRNAs that target
HMGA2. The data suggested that modification of histone patterns
bound to genomic DNA regions of miRNAs may regulate miRNA
expression by epigenetic control [31].
Taken together, the functions of the epigenetic regulatory
factors DNMT, HDAC, PcG and miRNAs overlap and cross-
regulate each other. Although the regulation of stem cell cellular
senescence by DNMTs has been established, the biological role of
DNMTs in stem cell self-renewal has yet to be elucidated. Here,
we demonstrate a role of DNMT during cellular senescence of
hUCB-MSCs, uncovering how epigenetic regulatory factors, such
as HDAC, PcG and miRNAs, are involved in DNMT activity.
Materials and Methods
Isolation and culture of hMSCs
The UCB samples were obtained from the umbilical vein
immediately after delivery, with the written informed consent of
the mother approved by the Boramae Hospital Institutional
Review Board (IRB) and the Seoul National University IRB(IRB
No. 0603/001-002-07C1). The hUCB-MSCs were isolated and
cultured as previously described [4,37]. Briefly, The UCB samples
were mixed with the Hetasep solution (StemCell Technologies,
Vancouver, Canada) at a ratio of 5:1, and then incubated at room
temperature to deplete erythrocyte counts. The supernatant was
carefully collected and mononuclear cells were obtained using
Ficoll density-gradient centrifugation at 2,500 rpm for 20 min.
The cells were washed twice in PBS. Cells were seeded at a density
of 2610
5 to 2610
6 cells/cm
2 on plates in growth media consisted
of D-media (Formula No. 78-5470EF, Gibco BRL) containing
EGM-2 SingleQuot and 10% fetal bovine serum (Gibco BRL).
After 3 days, non-adherent cells were removed. For long term
culture, cells were seeded at a density of 4610
5 cells/10 cm-plate
and subcultured cells when they reach 80,90% confluency.
Senescence-associated beta-galactosidase (SA b-gal)
staining
SA b-gal staining was carried out as described by Narita et al.,
with some modifications [38]. The MSCs were seeded on 6-well
plates at a density of 1610
5/well for late-passage cells and 5610
4/
well for early-passage cells. Cells were incubated for 3 d until
reaching the appropriate confluence. For siRNA or anti-miRNA
treatment, cells were seeded at a density of 2610
4/ml, and siRNA
or anti-miRNA was used to treat the cells at 50–60% confluence.
The cells were washed twice with PBS and fixed with 0.5%
glutaraldehyde in PBS (pH 7.2) for 5 min at room temperature.
Cellswerethen washed with PBScontainingMgCl2 (pH 7.2, 1 mM
MgCl2) and stained in X-gal solution (1 mg/ml X-gal, 0.12 mM
K3Fe[CN]6(Potassium Ferricyanide), 0.12 mM K4Fe[CN]6(Potas-
sium Ferrocyanide), 1 mM MgCl2 in PBS, pH 6.0) overnight at
37uC. The cells were washed twice with PBS, and images were
captured with a microscope (IX70, Olympus, Japan).
Western blot analysis
Western blot analyses of DNMT1, DNMT3a, DNMT3b,
BMI1, EZH2, p16
Ink4A, p21
WAF1/Cip1, CDK2, CDK4 and b-
actin were performed as described previously [39]. hUCB-MSCs
cultured with or without 5-AzaC(Sigma, USA) inhibitors for 1, 3, 5
or 7 d were lysed with 50 mM Tris-HCl buffer containing 0.1%
Triton X-100 freshly supplemented with a protease/phosphatase
inhibitor cocktail. Proteins were then separated using 7.5–15%
SDS-PAGE and transferred to nitrocellulose membranes at
350 mA for 5 h. Primary antibodies used to detect each proteins
are DNMT1(polyclonal, BD, 1:1000), DNMT3A(polyclonal,
Millipore, 1:1000), DNMT3B(polyclonal, Abcam, 1:1000),
BMI1[1.T.21](monoclonal, Abcam, 1:1000), EZH2[BD43](mo-
noclonal, Millipore, 1:1000), p16
Ink4A(polyclonal, Abcam, 1:1500),
p21
WAF1/Cip1[CP74](monoclonal, Millipore, 1:1000), CDK2(po-
lyclonal, Cell-signaling, 1:2000), CDK4[DCS156](monoclonal,
Cell-signaling, 1:2000) and b-actin[8H10D10](monoclonal, Cell-
signaling, 1:5000). All antibodies were used according to the
manufacturer’s instructions, and protein bands were detected
using an enhanced chemiluminescence detection kit (Amersham
Pharmacia Biotech, UK).
RT-PCR
Total cellular RNA was extracted from cells with TRIzol
reagent
TM (Invitrogen, USA), according to the manufacturer’s
instructions. cDNA was synthesized by adding the purified RNA
and oligo-dT primers to Accupower RT premix (Bioneer, Korea),
according to the manufacturer’s instructions. PCR was conducted
using Accupower PCR premix (Bioneer, Korea). The primer sets
sequences used for this study are supplied in Table S1. All PCR
products were analyzed by gel electrophoresis on 1.5% agarose
gels with ethidium bromide staining, followed by fluorescence
digitization using a Bio-Rad GelDoc XR system (Bio-Rad, USA).
Semi-quantitative RT-PCR was conducted by quantifying the
RT-PCR bands using ImageJ image analysis software (National
Institutes of Health, USA). Each gene was normalized against
RPL13A as a housekeeping gene control. At least three
independent analyses were carried out for each gene.
Real-time quantitative PCR
Real-time qPCR were performed using SYBRH Green (Applied
Biosystems, USA), according to the manufacturer’s protocol.
RPL13A was used as an internal control. All amplicons were
analyzed using Prism 7000 sequence detection system 2.1 software
(Applied Biosystems, USA).
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For methylation-specific PCR, genomic DNA was extracted
from cells with AccuprepH(Bioneer USA) according to the
manufacturer’s instructions. Bisulfite conversion of genomic
DNA was performed using the MethyCode
TM(Invitrogen USA)
according to the manufacturer’s instructions. The sodium bisulfite-
modified DNA was amplified using Accupower PCR premix
(Bioneer, USA). The primers used for each promoter were designed
through online web site (www.urogene.org/methprimer/) and
primer sequences were supplied in Table S3.
siRNA, anti-miRNA and mature miRNA transfection study
Transient transfection assays were performed using commer-
cially available specific siRNAs for inhibition of DNMT1 and
DNMT3b along with a non-targeting siRNA (ON Target plus
SMART pool, Dharmacon, USA). Inhibition or overexpression
of miRNAs was achieved by commercial antisense miRNAs or
mature miRNAs of hsa-miR-200c and hsa-miR-214 with an
appropriate miRNA precursor-negative control (mature miRNA:
Invitrogen, USA, anti-miRNA inhibitor: Ambion, USA, and
miRNA precursor-negative control #1, Ambion, USA). The
siRNA, anti-miRNA and mature miRNA transfections were done
according to the manufacturer’s instructions. In brief, cells were
seeded at a concentration of 2610
4/well, and siRNA-containing
medium (without the addition of antibiotics) was added when the
cells reached 50–60% confluence. Cells were incubated with
50 nM siRNA, 50 nM anti-miRNAs or 50 nM mature miRNAs
for 48 h or 96 h. To investigate the long-term effects of
inhibition, the cells were subcultured for 48–72 h after siRNA,
anti-miRNA or mature miRNA transfection. Subcultured cells
were stabilized for 24 h and incubated with siRNA, anti-miRNA
or mature miRNA for 48–72 h at the same concentration. After
inhibition, RNA extraction and subsequent RT-qPCR or SA b-
gal staining was performed for genetic or characteristic analyses,
respectively.
In vitro differentiation assay
In vitro differentiation into osteogenic, adipogenic and lineages
was performed as described previously [40,41]. Briefly, hUCB-
MSCs were initially cultured in growth medium containing
various concentrations of 5-AzaC and then shifted to adipogenic
medium (DMEM supplemented with 5% FBS, 1 mM dexameth-
asone, 10 mM insulin, 200 mM indomethacin and 0.5 mM
isobutylmethylxanthine) or to osteogenic medium (DMEM
supplemented with 5% FBS, 50 mM L-ascorbate-2-phosphate,
0.1 mM dexamethasone and 10 mM glycerophosphate). Intracel-
lular lipid accumulation as an indicator of adipogenic differenti-
ation was visualized by oil red O staining. After being
photographed, the oil red O was eluted with 100% isopropyl
alcohol and quantified with an ELISA plate reader(EL800, Bio-
Tek Instruments) at OD500. Osteogenic differentiation was noted
by positive staining with alizarin red S, which is specific for
calcium. Neural induction was performed as described by Jori
et al, with modifications [41,42]. Briefly, hUCB-MSCs were
initially cultured in pre-induction medium composed of DMEM,
5% FBS, 10 ng/ml basic fibroblast growth factor (bFGF) and
HDAC inhibitors. Cells were rinsed with PBS and shifted to the
neuronal induction medium consisting of 100 mM butyrated
hydroxyanisole (BHA), 50 mM forskolin, 2% dimethyl sulphoxide,
25 mM KCl, 2 mM valproic acid, 2%B27 supplement(Gibco
BRL), 10 ng/ml basic fibroblast growth factor(bFGF) and 10 ng/
ml platelet-derived growth factor(PDGF) in a base of DMEM.
Cells were maintained in induction medium for up to 24 h.
Immunocytochemistry
Immunocytochemical analyses of TUJ1 were performed. Cells
were cultured in neural pre-induction media with or without 5-
azaC. Neural induction was performed after 1day pre-induction
and fixed in 4% paraformaldehyde and permeabilized with 0.2%
Triton X-100 (Sigma Aldrich, USA). The cells were then
incubated with 10% normal goat serum (Zymed Laboratories
Inc., USA) and stained with antibodies against TUJ1 (1:200,
Abcam, UK), followed by incubation for 1 h with an Alexa 488-
labeled secondary antibody (1:1000; Molecular Probes, USA). The
nuclei were stained with Hoechst 33258 (1 mg/ml; 10 min), and
images were captured with a confocal microscope (Eclipse TE200,
Nikon, Japan).
Chromatin immunoprecipitation (ChIP) assays
The hUCB-MSCs were seeded in 10-cm plates at a density of
0.8–1610
5 per plate and cultured with or without 5-azaC for 1 or
3 d. ChIP assays were performed according to the manufacturer’s
protocol (ChIP assay kit, Upstate Biotechnology, USA). Chroma-
tin was immunoprecipitated using antibodies, according to the
manufacturer’s instructions. Real-time qPCR was performed at a
final template dilution of 1:50. The primer sequences used in the
ChIP assays in this study are supplied in Table S2.
Measurement of proliferation potential and cell cycle
distribution
The effects of cellular senescence or 5-AzaC on MSC
proliferation were measured using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich, USA)
assay as described previously [39]. In brief, cells were plated on 24-
well plates at a density of 2610
4/ml and cultured with or without
5-AzaC for 1,2 or 3days. At the end of the incubation, 50 mlo f
MTT stock solution (5 mg/ml) was added, and the plates were
incubated for another 4 h at 37uC. Formazan crystals were
solubilized with DMSO, and the absorbance was measured with
an EL800 microplate reader (BIO-TEK Instruments, USA).
Flow cytometry cell cycle analysis using propidium iodide
staining was also performed as previously described [21]. Briefly,
MSCs in exponential growth phase were treated with HDAC
inhibitors for 3 days and then harvested by trypsinization. Cells
were washed with ice-cold PBS and then fixed with 70% ethanol
at 220uC and stained with 50 mg/ml of propidium iodide in the
presence of 100 mg/ml RNase A for 30 min. Cell cycle
distribution was analysed using the FACSCalibur system (Becton
Dickinson, Franklin Lakes, NJ, USA).
Statistical analysis
All experiments were conducted at least in triplicate (n=3), and
results are expressed as the mean 6 SD. Statistical analysis was
conducted via analysis of variance (ANOVA), followed by
Student’s t-test. p,0.05 was considered to be significant.
Results
Replicative senescence of human MSCs
To characterize cellular senescence in human MSCs, we
induced replicative senescence of hUCB-MSCs and human
adipose tissue -derived multipotent stem cells (hAD-MSCs) by
repeated sub-culture. A definite phenotype of cellular senescence
was confirmed in hUCB-MSCs at passages higher than 15 (p15),
as shown by SA b-gal staining (Fig. 1a and Fig. S1a). A remarkable
difference in the cellular proliferation rate between p6 and p16
was confirmed by an MTT assay (Fig. 1b) and cell cycle
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(Fig. S2). Based on these data, we hereafter refer to p6–p7 and
p15–p16 in the following experiments as the early and late state,
respectively. To investigate the changes in expression levels of
epigenetic modifying enzymes, DNMTs were analyzed by real-
time PCR and western blot analysis. Both mRNA and protein
levels of CDK inhibitors, p16
INK4A and p21
CIP1/WAF1 were
increased. However, DNMT1 and DNMT3b were decreased in
the senescent hUCB-MSCs (Fig. 1c and 1d), and there was no
significant change in DNMT3a expression levels during senes-
cence. hAD-MSCs also showed similar pattern of gene expressions
with hUCB-MSCs (Fig. S3).
DNMT inhibition induces cellular senescence, cell cycle
arrest and decreased multipotency
During spontaneous cellular senescence of hUCB- and hAD-
MSCs, DNMT1 and DNMT3b expression levels were decreased,
and p16
INK4A and p21
CIP1/WAF1 levels were increased. The over-
expression of DNMTs has been reported in several cancercell lines,
and DNMT inhibitors such as 5-AzaC have been well studied.
Inhibition of DNMTs decrease cellular growth and induce
apoptosis of cancer cells [43,44]. However, there are no studies
explaining the relationship between DNMTs and spontaneous
senescence of normal adult stem cells. In order to elucidate whether
the inhibition of DNMTs could induce cellular senescence of
hUCB- and hAD-MSCs, we treated hUCB- and hAD-MSCs with
the DNMT inhibitor 5-azacytidine (5-AzaC) and investigated
phenotypic changes in the cells. DNMT inhibition by 5-AzaC
treatment induced cellular senescence, as shown by SA b-gal
staining (Fig. 2a, 2d, Fig. S1b, Fig. S4a and S4c), and decreased the
cellular proliferation rate in a dose-dependent manner, as shown by
an MTT assay (Fig. 2b and Fig. S4b). Cellular senescence is closely
related to a loss of stemness. To determine the role of DNMT on
the stemness of hUCB-MSCs, we investigated multipotency after
treatment with 5-AzaC. We differentiated MSCs into osteogenic,
adipogenic and neural lineages after 5-AzaC treatment and found
that the differentiation of MSCs to all three lineages were decreased
after 5-AzaC treatment, indicating that DNMT inhibition
decreased the differentiation capacity of hUCB-MSCs (Fig. S5).
To investigate time-dependent phenotypic and gene expression
changes, we treated hUCB- and hAD-MSCs with 5-AzaC for 1, 3,
5 and 7 days and performed SA b-gal staining, RT-qPCR and
western blot analyses (Fig. 2c–2d, Fig. S1c and S4d). DNMT
isoforms began to decrease at 1 day after treatment with 5-AzaC.
SA b-galactosidase activity and expression levels of p16
INK4A and
p21
CIP1/WAF1 were increased at day 3 of 5-AzaC treatment, and
prominent changes were observed after 5 days of treatment with 5-
AzaC. Because p16
INK4A and p21
CIP1/WAF1 are CDK inhibitors
that block G1 phase progression [45], we analyzed cell cycle
progression by FACS analysis after treatment of hUCB-MSCs with
5-AzaC for 2 days in various concentrations to elucidate the effects
of CDK inhibitors on the cell cycle during cellular senescence
induced by DNMT inhibition. The results showed that DNMT
inhibition induced G1 phase arrest in hUCB-MSCs in a dose-
dependent manner. CDK2 and CDK4, which are direct targets
of p16
INK4A and p21
CIP1/WAF1, were decreased, as shown by
western blot analysis. Taken together, increased p16
INK4A and
p21
CIP1/WAF1 as a result of inhibition of DNMTs down-regulated
CDK2 and CDK4 expression and induced G1 phase cell cycle
arrest in hUCB-MSCs (Fig. 2e).
Figure 1. Replicative senescence of hUCB-MSCs. (a) MSCs undergo replicative senescence upon repeated (more than 15 passages) subculturing
in vitro, as shown by SA b-gal staining. (b) Proliferation rates of MSCs in early and late passages were measured by MTT assay. (c–d) The expression of
DNMT1, DNMT3A and DNMT3B was down-regulated, whereas p16
INK4A was up-regulated during repeated subculture-induced senescence of MSCs,
as shown by real-time qPCR (c) and immunoblot analysis (d). * and ** represent statistical significance at the levels of p,0.05 and p,0.01,
respectively.
doi:10.1371/journal.pone.0019503.g001
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In spontaneous and 5-AzaC-induced cellular senescence,
DNMT1 and DNMT3b were consistently decreased. To elucidate
the effects of each DNMT isoform, inhibition of DNMT1 and
DNMT3b was performed using specific siRNAs. Phenotypic and
gene expression changes were investigated to confirm the
reproducibility of DNMT inhibition (Fig. 3a–d). Specific inhibition
of DNMT1 and DNMT3b induced cellular senescence, as shown
by SA b-gal staining (Fig. 3b and Fig. S1d) and increased
expression levels of p16
INK4A. DNMT1 and DNMT3b inhibition
also induced p21
CIP1/WAF1 mRNA expression. Consistent with the
results presented in Figure 2, these data showed that the inhibition
of DNMT activity increases expression levels of CDK inhibitors
and causes cellular senescence of hUCB-MSCs.
DNMT inhibition modifies histone marks, transcriptional
enzymes and the CpG island methylation status in the
CDKi promoter regions
To investigate the effect of DNMT inhibition on the epigenetic
status of CDKi (p16
INK4A and p21
CIP1/WAF1) promoter regions,
we confirmed the methylation status of CpG islands and the
changes of histone marks after 5-AzaC treatment. The CpG
islands in the promoter regions of p16
INK4A and p21
CIP1/WAF1
were investigated with an online web site (http://cpgislands.usc.
edu/) according to the following lower limits: %GC=50,
Figure 2. DNMT inhibition induced cellular senescence. (a) hUCB-MSCs were treated with the DNMT inhibitor 5-AzaC for 7 days. DNMT
inhibition by 5-AzaC induced cellular senescence, as shown by SA b-gal staining. (b) After 5-AzaC treatment for 1, 2 and 3 days, an MTT assay was
performed. (c–d) 5-AzaC increased p16
INK4A and p21
WAF1/Cip1 and decreased DNMT1, DNMT3A and DNMT3B, as shown by real-time qPCR analysis (c)
and western blot analysis (d). 5-AzaC treatment for 1, 3, 5 and 7 days induced cellular senescence of hUCB-MSCs, as shown by SA b-gal staining (d). (e)
After a 2 day treatment with 5-AzaC, FACS analysis was performed, as described in the Materials and Methods section. 5-AzaC treatment induced G1
phase cell cycle arrest in a dose-dependent manner. CDK2 and CDK4 expression levels were confirmed by western blot analysis.
doi:10.1371/journal.pone.0019503.g002
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tance=100. A total of 5 and 10 CpG islands were found within
50 kbp upstream of the promoter regions of p16
INK4A and
p21
CIP1/WAF1, respectively. Methylation of the CpG islands on
these promoter regions was investigated after 5-AzaC treatment,
and we found decreased methylation of the CpG islands.
However, there were profound differences in the CpG methylation
status between the p16
INK4A and p21
CIP1/WAF1 promoter regions
of untreated control hUCB-MSCs. The CpG islands in the
p16
INK4A promoter region were highly methylated, as demon-
strated by hardly detectable levels of unmethylated product bands
(Figure 4B). However, the ratio of methylated CpG islands in the
p21
CIP1/WAF1 promoter region was approximately 50% according
to the product band intensity. This result suggested that
demethylation of CpG islands would have more of an effect on
the regulation of p16
INK4A expression than p21
CIP1/WAF1
expression (Fig. 4a and 4b) because the p16
INK4A promoter is
more highly methylated than the p21
CIP1/WAF1 promoter at basal
levels in hUCB-MSCs. Considering that the DNA methylation
status is highly related to histone modification, we also investigated
the histone modification status of the p16
INK4A and p21
CIP1/WAF1
promoter regions after inhibition of DNMTs by 5-AzaC
treatment. We found that the active histone forms, acetyl H3
and acetyl H4, were increased. However, inactive forms of
histones, such as H3K9Me3 and H3K27Me3, were decreased in
the p16
INK4A and in p21
CIP1/WAF1 promoter regions following
inhibition of DNMTs. H3K4Me3, an active histone form, did not
change following 5-AzaC treatment (Fig. 5c–d). Binding of EZH2,
a polycomb protein with methyltransferase activity that methylates
histone H3K9 and H3K27, were decreased. However, binding of
RNA polymerase II was significantly increased on the p16
INK4A
and p21
CIP1/WAF1 promoter regions after 5-AzaC treatment
(Fig. 5e–f). These data indicate that DNMT regulates p16
INK4A
and p21
CIP1/WAF1 expression levels by both direct modification of
DNA methylation and indirect histone modifications on the
p16
INK4A and p21
CIP1/WAF1 promoter regions.
DNMT inhibition decreased PcG expression
Considering the decreased EZH2 binding on the p16
INK4A and
p21
CIP1/WAF1 promoter regions, we assessed whether DNMT
inhibition affects the expression levels of EZH2 and BMI1, a
PRC1 protein that is recruited to the PRC2 binding site and
maintains transcriptional repression. As we have previously
reported, EZH2 and BMI1 expression levels were significantly
decreased in replicative senescence (Fig. 5a). After inhibition of
DNMT by 5-AzaC treatment, we observed decreased EZH2 and
BMI1 expression levels (Fig. 5b). Specific inhibition of DNMT1
and DNMT3b with siRNA also consistently decreased expression
levels of EZH2 and BMI1 (Fig. 5c).
PcG-targeting microRNAs were upregulated after DNMT
inhibition
DNMT is well known to suppress gene expression by DNA
methylation. Thus, one may speculate that the effect of DNMT
inhibition on p16
INK4A and p21
CIP1/WAF1 expression is due to
transcriptional reactivation. In this context, decreases of BMI1 and
EZH2 by inhibition of DNMTs should have negative mediators,
which may increase during DNMT inhibition. Considering that
BMI1 and EZH2 expression is regulated at the mRNA and protein
level, the mediators, if any, would regulate mRNA and/or protein
expression of BMI1 and EZH2. Given that miRNAs have common
inhibitory functions on gene expression by targeting mRNAs, they
could be reasonable candidates as inhibitory mediators. To confirm
whether miRNAs are involved in the regulation of PcG by DNMT
inhibition, we observed expression levels of miRNAs in both
spontaneous and 5-AzaC-induced cellular senescence. It is well
known that miR-214 targets EZH2 and that miR-200c targets
BMI1[33,46]. By real-time qPCR analysis,we confirmed that miR-
200c and miR-214 were up-regulated in senescent hUCB-MSCs
(Fig. 6a). Because the significant decrease of EZH2 and BMI1
occurs after 3 days of treatment with 5-AzaC, we investigated
miRNA expression levels at 1, 3 and 7 days after treatment with 5-
Figure 3. Specific inhibition of DNMT1 and DNMT3b induced cellular senescence. (a) Specific inhibition of DNMT1 and DNMT3B using
siRNA was performed, as described in the Materials and Methods section. The expression levels of DNMT1 and DNMT3B were decreased, as shown by
real-time PCR analysis. (b) Specific down-regulation of DNMT1 and DNMT3B caused cellular senescence in MSCs, as shown by SA b-gal staining. (c–d)
The expression levels of p16
INK4A and p21
CIP1/WAF1 were confirmed by real-time qPCR (c) and western blot analysis (d).
doi:10.1371/journal.pone.0019503.g003
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increased at the time points indicated (Fig. 6b and 6c). To confirm
whether the targets of miR-200c and miR-214 are BMI1 and EZH2,
respectively, in hUCB-MSCs, we performed miRNA inhibition and
overexpression experiments using transient transfection of anti- and
mature-miRNA oligonucleotides. After overexpression of miR-200c
and miR-214, MSCs underwent cellular senescence, as shown by SA
b-gal staining, and BMI1 and EZH2, the respective targets of miR-
200c and miR-214 were decreased, as shown by real-time qPCR
(Fig. 6d and 6e). In addition, inhibition of miR-214 using antisense
oligonucleotide transfection increased EZH2 expression (Fig. 6e).
However, after inhibition of miR-200c, BMI1 expression was not
changed at the mRNA level. Although inhibition of miR-200c did
notyieldconsistentresults,overexpressionofboth miRNAsdecreased
their respective target (BMI1 and EZH2) at the mRNA level,
suggesting that overexpressed miRNA during cellular senescence
regulates the expression levels of BMI1 and EZH2.
DNMT inhibition modifies the CpG island methylation
status, histone marks and transcriptional enzymes in the
vicinity of genomic DNA regions of miRNAs
According to the results shown in Figure 4, DNMT inhibition
induced the expression of miR-200c and miR-214, which target
PcGs. Recalling that the major function of DNMT involves
epigenetic regulation, we investigated the epigenetic status of the
genomic regions of miRNAs by measuring the CpG island
methylation status, histone marks and the related binding proteins
at the genomic regions of miRNAs. CpG islands in the vicinity of
miRNAs were investigated using the previously mentioned online
website. After DNMT inhibition by 5-AzaC for 3 days,
methylation of CpG islands in the vicinity of miRNA genomic
regions was investigated by methyl-specific PCR. We observed
that methylation of CpG islands was decreased after DNMT
inhibition (Fig. 7a and 7b). After DNMT inhibition by 5-AzaC for
1 and 3 days, we performed ChIP analysis followed by real-time
qPCR analysis using primers against the genomic regions of
miRNAs. Binding of active histone marks, acetyl histone H3 and
H4 and H3K4Me3 were significantly increased in both miRNA
genomic regions. However, the fold enrichment of inactive histone
marks, histone H3K9Me3 and H3K27Me3 were significantly
decreased in both miRNA genomic regions (Fig. 7c and 7d).
Although EZH2 is a target of miR-214, EZH2 itself could be
involved with the regulation of histone H3K27 methylation at
miRNA genomic regions in a negative feedback manner. To
confirm this, we also investigated the binding level of EZH2 to the
genomic regions of miRNAs and found that EZH2 binding to
miRNA genomic regions was decreased after 5-AzaC treatment
(Fig. 7e). To obtain direct evidence of the transcriptional
regulation of miRNA expression, RNA polymerase II (PolII)
enrichment on the miRNA genomic region was investigated, and
we confirmed an increase of PolII binding (Fig. 7f).
Discussion
In this study, we determined that DNMTs regulate the cellular
senescence of hUCB-MSCs by controlling the expression of
Figure 4. DNMT inhibition modified histone marks, transcriptional enzymes and the CpG island methylation status in the CDKi
promoter regions. (a–b) After treatment with 5-AzaC for 5 days, methyl-specific PCR was performed. (a) Schematic diagrams indicate locations of
each primer on CDKi promoter regions. (b) Methyl-specific PCR was performed as described in the Materials and Methods section. M: methyl primer,
U: unmethyl primer. (c–f) After treatment with 5-AzaC for 3 days, ChIP analysis was performed using antibodies targeting the indicated protein
(AcetylH3, AcetylH4, H3K4Me3, H3K9Me3, H3K27Me3, PolII and EZH2). (c) Schematic diagrams indicate the locations of each primer on genomic DNA.
(d–f) Fold enrichment of indicated proteins on the promoters of p16
INK4A and p21
WAF1/Cip1 were investigated by real-time PCR.
doi:10.1371/journal.pone.0019503.g004
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INK4A and p21
CIP1/WAF1 through epigenetic modification. In
addition to this, we also unveiled the mechanism how DNMT
regulates BMI1 and EZH2 by controlling the expression of
miRNAs during cellular senescence.
We found that the DNMT isoforms DNMT1 and DNMT3B
were decreased during the cellular senescence of hUCB-MSCs.
Stem cells and cancer cells are able to expand while maintaining
undifferentiated properties. Although it is well known that the
over-expression of DNMT suppresses p16
INK4A in various cancer
cells, the regulatory roles of DNMT on stem cell aging and self-
renewal have not been well studied. There are two studies showing
the involvement of DNMTs in normal human fibroblast aging
[47,48]. In this study, we first clarified the involvement of DNMT
on the cellular senescence of hUCB-MSCs. The inconsistent
changes in expression levels among the DNMT isoforms, as shown
in fig. 2b, have already been reported in several studies. Chen, C.
et al. showed that DNMT1 and DNMT3B mRNAs were
overexpressed, although DNMT3A expression was not changed
in primary and recurrent epithelial ovarian carcinoma [41]. Datta,
J et al. demonstrated that Dnmt3b and Dnmt1 make a co-
repressor complex that exhibits de novo DNA methyltransferase
activity. Dnmt3a is related to Hdac1 and HMTase activity
[49,50]. Vinken, M. et al. reported that DNMT3A was decreased
during Fas-mediated hepatocyte apoptosis, whereas DNMT1 and
DNMT3B showed no changes [51]. According to our results,
decreases in DNMT1 and DNMT3B were associated with
spontaneous senescence of hUCB-MSCs, but DNMT3A was
not. Specific inhibition of both DNMT1 and DNMT3B increased
p16
INK4A expression and SA b-gal activity. However, in
DNMT3B-inhibited cells, some apoptotic cell death was observed.
Considering that DNMT inhibition by 5-AzaC did not cause
apoptosis, the extent of DNMT3B inhibition could have shifted
cellular senescence to apoptosis. Another possibility is that
DNMT3B inhibition alone induces apoptosis, but the overall
down-regulation of DNMT isoforms could induce cellular
senescence through another pathway.
Inhibition of DNMTs increased the expression levels of CDK
inhibitors p16
INK4A and p21
CIP1/WAF1, followed by G1 phase cell
cycle arrest, a decreased cell proliferation rate and an induction of
cellular senescence. Osteogenic, adipogenic and neural differen-
tiation abilities of MSCs were also decreased after DNMT
inhibition. In addition, MSCs are able to differentiate into
myogenic lineage [52,53,54,55,56,57,58,59]. It was reported that
epigenetic modifying drugs induces nonmesenchymal differentia-
tion. Valproic acid, a HDAC inhibitor was used for neural
induction of MSCs [60,61], and 5-AzaC is a well known inducer of
myogenic differentiation of MSCs [54,55,56,57,58,59]. There are
a number of studies that report DNMT inhibition causes bone
marrow derived multipotent progenitor cells and embryonic stem
cells to differentiate into endothelial cells [62,63]. Taken together,
5-AzaC has decreased the differentiation potential of hUCB-
MSCs into adipogenic and osteogenic lineages as well as neuronal
cells in the present study. Because we did not examine whether 5-
AzaC affects myogenic and endothelial differentiation of hUCB-
MSCs, there are still possibilities that the role of 5-AzaC in MSC
differentiation is cell type specific. This would be worthy of further
research to extend our understandings of regulation mechanisms
of MSC differentiation.
In the present study, we first elucidated how DNMT regulates
p16
INK4A and p21
CIP1/WAF1 and induces cellular senescence of
hUCB-MSCs. According to our results, DNMT inhibition
induced histone modulation and decreased DNA demethylation
at the p16
INK4A and p21
CIP1/WAF1 promoter regions. As
methylated DNA is bound by methyl-CpG binding protein
(MeCP) complexes that include HDACs, DNA demethylation
followed by histone acetylation on the promoter regions after
DNMT inhibitor treatment is reasonable. According to one
report, DNMT3A is associated with HDAC1 and HMTase,
suggesting that DNMT3A could be one of the mediators bridging
DNA methylation and histone acetylation/methylation. Decreases
in both EZH2 expression levels and EZH2 enrichment at the
p16
INK4A and p21
CIP1/WAF1 promoter regions supports our ChIP
results, which showed the demethylation of H3K9Me3 and
H3K27Me3 during cellular senescence. In our supplementary
data (Fig. S6), KDM2B (histone H3K4 demethylase) was
decreased and JMJD3 (histone H3K27 demethylase) was increased
in the replicative or DNMT inhibitor-induced senescent state
when compared to early passage or control cells. Considering that
the expression levels of genes reflect their global activity in the
cells, these changes in histone demethylase expression levels also
support the changes in histone H3K4 or H3K27 methylation on
promoter regions, which were investigated in this study. In the
case of DNA methylation, according to the results of the methyl-
specific PCR in the present study, the p16
INK4A promoter region
was more methylated than the p21
CIP/1WAF1 promoter region. As
a consequence, the demethylation of of p16
INK4A promoter region
occurred more highly than that of p21
CIP/1WAF1 after DNMT
inhibitor treatment.
In fact, the reported regulatory mechanisms of p16
INK4A and
p21
CIP1/WAF1 vary according to the cell line studied. In various
cancer cell lines, the DNMT isoforms DNMT1 and DNMT3B
are up-regulated, and as a result, the promoter region of
p16
INK4A is hypermethylated. In this case, inhibition of DNMT
up-regulates the expression level of p16
INK4A by controlling the
DNA methylation status at the p16
INK4A promoter region
[8,10,11]. Another mechanism that regulates p16
INK4A expres-
Figure 5. DNMT inhibition decreased PcG expression. (a) EZH2
and BMI1 expression levels were investigated by real-time qPCR (left)
and western blot (right) in early and late passages of hUCB-MSCs. (b)
EZH2 and BMI1 expression levels were investigated by real-time qPCR
(left) and western blot (right) after the indicated duration treatment of
5-AzaC. (c) Expression levels of BMI1 and EZH2 were investigated by
real-time qPCR after DNMT1 and DNMT3B inhibition.
doi:10.1371/journal.pone.0019503.g005
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previous study, we have reported that HDAC inhibition caused
increased p16
INK4A expression levels, followed by demethylation
of histone H3K27me3, which is a repressive histone mark
regulated by a balance of the expression levels between PcGs and
JMJD3 [4]. There are several studies that suggest that p16
INK4A
expression is also regulated by histone acetylation. Zhou R et al.
reported that p16
INK4A expression could be regulated by the
recruitment of HDACs in human fibroblasts. Histone acetylation
is a major mechanism for p21
CIP/1WAF1 regulation in gastric
cancer cell lines [64]. However, the DNA methylation status of
the p21
CIP/1WAF1 promoter region and the involvement of
DNMT in the regulatory mechanism are different among cell
lines. In Rat-1 cells and rhabdomyosarcomas, increased methyl-
ation at p21
CIP/1WAF1 promoter regions has been reported.
However, several studies indicated that the hypermethylation of
Figure 6. PcG-targeting microRNAs were upregulated after DNMT inhibition. (a–c) To confirm the expression levels of PcG-targeting
microRNAs in early and late passage MSCs and 5-AzaC-treated MSCs, real-time qPCR analysis was performed. Relative expression levels of mature
microRNA 200c and 214 in early and late passage (a) and 1, 3 and 7day, 5-AzaC-treated hUCB-MSCs (b) were visualized. Relative expression levels of
precursor microRNA 200c and 214 in 1–3 day, 5-AzaC-treated hUCB-MSCs were visualized (c). (d–e) miR200c and miR-214 inhibition and
overexpression studies were performed. (d) Overexpression of both miRNAs induced cellular senescence of hUCB-MSCs, as shown by SA b-gal
staining. (e) After transfection of anti- and mature-miRNA oligonucleotides, the expression levels of each miRNA and EZH2 and BMI1 were evaluated
by real-time qPCR.
doi:10.1371/journal.pone.0019503.g006
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CIP/1WAF1 was not the main mechanism by which
p21
CIP/1WAF1 expression was being regulated [65,66]. Although
Young et al. reported that DNMT inhibition caused cell cycle
arrest and p21
CIP/1WAF1 overexpression in normal human
fibroblasts [66], Milutinovic et al. showed that inhibition of
DNMT resulted in the rapid induction of p21
CIP/1WAF1 without
involvement of DNA demethylation in the p21
CIP/1WAF1
promoter in the A549 human non-small cell lung cancer cell
line [67]. Shin et al. reported that the promoter of the
p21
CIP/1WAF1 gene was not methylated in gastric cancer cells.
This demonstrates that the inactivation of p21
CIP/1WAF1 in gastric
cancer cells might occur independently of the DNA methylation
status of the p21
CIP/1WAF1 promoter region [64].
DNMT inhibition by 5-AzaC and specific siRNAs induced
cellular senescence, followed by a decrease in BMI1 and EZH2.
To date, there is no report that shows the role of DNMT in the
regulation of BMI1 and EZH2. Instead, some studies have shown
that BMI1, EZH2 and DNMT work together to repress gene
expression by histone modulation or DNA methylation [18,19].
We first elucidated that DNMT was associated not only with the
functional activities of PcG but also with BMI1 and EZH2
expression. Regulation of miRNAs that target BMI1 and EZH2 by
DNMT during cellular senescence is also a novel finding in this
study. MiR-200c and miR-214 were previously reported to target
BMI1 and EZH2, respectively, in studies that showed that miR-
214 targets Ezh2 in skeletal muscle and embryonic stem cells and
that miR-200c targets BMI1 in breast cancer stem cells [33,46].
We confirmed that miR-200c and miR-214 were up-regulated in
senescent hUCB-MSCs. Next, to confirm whether miR-200c and
miR-214 regulate BMI1 and EZH2 expression levels in hUCB-
MSCs, we performed transient transfection of antisense or mature
miRNA oligonucleotides. The results showed that anti- and
mature-miR-214 regulated EZH2 expression at the mRNA level.
Transfection of mature miR-200c also decreased BMI1 expres-
sion. However, anti-miR-200c did not regulate BMI1 mRNA
expression levels. Because the absolute quantity of miR-200c was
relatively lower than that of miR-214 in early passages of hUCB-
MSCs and expression of miR-200c would be in an inhibited state
in early passage cells compared to senescent cells, additional miR-
200c inhibition may have no effect on BMI1 expression. To
confirm this hypothesis, additional miRNA inhibition studies
should be performed in senescent cells in which miRNAs are in an
up-regulated state.
Considering that DNMT is an epigenetic modulator of
transcriptional activity, we questioned whether the miRNAs were
regulated by transcriptional reactivation. The increase of precur-
sor miRNAs during cellular senescence supported this possibility.
To answer this question, we investigated the DNA methylation
status and histone modulation of the miRNA regions after
treatment of 5-AzaC. A decrease in the DNA methylation status
was observed in the vicinity of the miRNA genomic region after 5-
AzaC treatment. In addition, DNMT inhibition increased active
histone forms, acetyl histone H3 and H4, histone H3K4Me3 and
decreased H3K9 trimethylation (H3K9Me3) and H3K27Me3 in
the proximity of the genomic region of miRNAs. A significant
increase in RNA polymerase II bound on the indicated locations
shows that the transcriptional activities might be increased at both
miR-200c and miR-214 genomic regions. A decrease in EZH2
binding to the genomic region of miRNAs indicated that these
miRNAs and their target PcGs affect each other reciprocally.
Recently, it has been uncovered that the genomic regions of
miRNAs, which act as tumor suppressors, are hypermethylated in
Figure 7. DNMT inhibition modified histone marks, transcriptional enzymes as well as the CpG island methylation status in the
vicinity of miR-200c and 214 genomic regions. (a–b) After treatment with 5-AzaC for 5 days, methyl-specific PCR was performed. (a) Schematic
diagrams indicate locations of each primer in the vicinity of miR-200c and -214 genomic regions. (b) Methyl-specific PCR was performed as described
in the Materials and Methods section. M: methyl primer, U: unmethyl primer. (c–f) After treatment with 5-AzaC for 3 days, ChIP analysis was
performed using antibodies targeting to the indicated proteins (AcetylH3, AcetylH4, H3K4Me3, H3K9Me3, H3K27Me3, PolII and EZH2). (c) Schematic
diagrams indicate the locations of each primer on genomic DNA. (d–f) Fold enrichment of indicated proteins in the vicinity of miR-200c and -214
genomic regions were investigated by real-time qPCR.
doi:10.1371/journal.pone.0019503.g007
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of miRNAs and are emerging as a significant topic in the cancer
cell field [68,69]. MiR-200c, which targets BMI1, is one of the
important miRNAs that are epigenetically repressed in breast
cancer cells. This study shows that miR-200c and miR-214 are
related not only to cancer cells but also to the cellular senescence
of MSCs, linking DNA methylation and PcG-related histone
modification.
Taken together, we first report here that DNMTs have a
critical role in regulating cellular senescence of hUCB-MSCs
through controlling PcG-targeting miRNAs and p16
INK4A and
p21
CIP1/WAF1 expression epigenetically as summarized in Fig. 8.
The regulation of miRNAs by DNMT enables us to explain how
PcGs are downregulated after DNMT inhibition and suggest
another linking mechanism between DNMT inhibition and
histone modification. Extending this study, it would be mean-
ingful to find up-regulated miRNAs, which target down-regulated
proteins, and confirm their epigenetic changes after DNMT
inhibition.
Supporting Information
Figure S1 Quantification of SA-beta-gal positive cells.
SA-beta-gal positive cells were quantified through counting cells in
at least 3 microscope images for each group and presented in
graph(a; Fig 1a, b;Fig 2a, c;Fig 2d, d;Fig 3b).
(TIF)
Figure S2 Cell cycle analysis of early and late passaged
hUCB-MSCs. To compare cell cycle status of early and late
passaged hUCB-MSCs, FACS analysis was performed, as
described in the Materials and Methods section.
(TIF)
Figure S3 Changes of gene expression levels in senes-
cent hAD-MSCs. Primary culture and long term culture of hAD-
MSCs were performed as described in Methods S1. The
expression of DNMT1, DNMT3A, DNMT3B, BMI1 and
EZH2 was down-regulated, whereas p16
INK4A was up-regulated
during repeated subculture-induced senescence of hAD-MSCs, as
shown by RT-PCR. We quantified the results of RT-PCR
analyses by using image analysis software (imageJ) and values
presented as graph. * and ** represent statistical significance at the
levels of p,0.05 and p,0.01, respectively.
(TIF)
Figure S4 DNMT inhibition induced cellular senescence
of hAD-MSCs. hAD-MSCs were treated with the DNMT
inhibitor 5-AzaC. DNMT inhibition by 5-AzaC induced mor-
phological change and cellular senescence, as shown by SA b-gal
staining. (a, c) After 5-AzaC treatment for 3 days, an MTT
assay(b) and realtime qPCR analysis(d) were performed.
(TIF)
Figure S5 5-AzaC-induced cell cycle arrest and de-
creased multipotency. Cells were pretreated with 5-AzaC for
the indicated time and dose. Osteogenic, adipogenic and neural
induction were performed, as described in the Materials and
Methods section. (a) 5-AzaC treatment decreased the osteogenic
differentiation of hUCB-MSCs, as shown by alizarin red S staining
after 3 weeks of induction with osteogenic medium. RT-PCR
analysis of the osteogenic marker type 1 collagen (Col-1) was
performed, and semi-quantification of at least three independent
assays was completed and visualized using ImageJ image analysis
software. (b) After adipogenic induction, lipid droplets were
visualized using oil red O staining. After being photographed, oil
red O was eluted, and absorbance was measured. RT-PCR
analysis of the adipogenic marker, aP2, was performed, and semi-
quantification of at least three independent assays was performed
and visualized using ImageJ image analysis software. (c) After 1
day of neural induction, morphological changes were observed
using an inverted microscope. TUJ1 neurofilaments were
visualized using immunocytochemistry, and levels of the PAX6
transcription factor, which is expressed during neurogenesis, was
assessed using RT-PCR.
(TIF)
Figure S6 Expression levels of histone demethylases in
early/late passages and 5-AzaC-treated hUCB-MSCs.
RT-PCR analysis was performed to confirm the expression levels
of histone demethylases, KDM2B and JMJD3.
(TIF)
Methods S1 Isolation and culture of hAD-MSCs.
(DOCX)
Figure 8. Schematic diagram describing the relationship between miRNAs, PcGs, p16 and p21 and how transcriptional regulation
of miRNAs, p16
INK4A and p21
CIP1/WAF1 occurs in DNMT inhibitor-mediated senescent MSCs. (a) DNMT inhibition increases p16
INK4A and
p21
CIP1/WAF1 expression directly through DNA demethylation, indirectly through an unknown pathway and, over time, induces cellular senescence.
The regulation of miRNAs, which target PcG proteins, is one of the indirect pathways that increase p16
INK4A and p21
CIP1/WAF1 expression. (b) DNMT
inhibition induces CpG island demethylation, increases active histone forms and decreases inactive histone forms in the promoter region of CDK
inhibitors and in the proximity of miRNAs in hUCB-MSCs. Pri-miRNA refers to primary-miRNA.
doi:10.1371/journal.pone.0019503.g008
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Table S2 Promoter primer sequences used for ChIP
analysis
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Table S3 Primers used for methyl specific PCR
(DOCX)
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